The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Efficacy of two one‐week rabeprazole/levofloxacin‐based triple therapies for Helicobacter pylori infection
Open accessAbstract
Background: One‐week low‐dose proton pump inhibitor‐based triple therapies have usually proved to be effective treatments for Helicobacter pylori infection. Aim: To investigate the eradication efficacy, safety profile and patient compliance of two triple therapies containing a standard dose of rabeprazole and a new fluoroquinolone, levofloxacin. Methods: One hundred patients referred to us for gastroscopy, who were H. pylori‐positive, were consecutively recruited in a prospective, open‐label study. The enrolled patients were randomised to receive a seven‐day course of rabeprazole 20 mg o.d. plus levofloxacin 500 mg o.d. and either amoxycillin 1 g b.d. (RLA group) or tinidazole 500 mg b.d. (RLT group). Their H. pylori status was assessed by means of histology and rapid urease test at entry, and by 13 C‐urea breath test 8 weeks after the end of treatment. Results: All 100 enrolled patients completed the study. Forty‐six of 50 patients treated with RLA (both PP and ITT analysis: 92%; 95% CI: 81–98%) and 45 of 50 with RLT (both PP and ITT analysis: 90%: 95% CI: 78–97%), became H. pylori‐negative. Slight or mild side‐effects occurred in 4 (8%) patients of the RLA group and in 5 (10%) of the RLT group. Conclusions: This study demonstrates the efficacy of two 1‐week rabeprazole‐based triple therapies including levofloxacin to eradicate H. pylori. These regimens prove to be safe, well‐tolerated, and achieved good eradication rates. Levofloxacin may be an effective alternative to clarithromycin in triple therapy regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hentschel, E., Brandstatter, G., Dragosics, B., Hirschl, A. M., Nemec, H., Schutze, K., Taufer, M., & Wurzer, H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302043280503 · Cited by 708
Cited by
Megraud, F., Coenen, S., Versporten, A., Kist, M., Lopez-Brea, M., Hirschl, A. M., Andersen, L. P., Goossens, H., Glupczynski, Y., & on behalf of the Study Group participants (2013) · Gut · doi:10.1136/gutjnl-2012-302254 · Cited by 839
Treatment of Helicobacter pylori Infection
O'Connor, A., Gisbert, J., & O’Morain, C. (2009) · Helicobacter · doi:10.1111/j.1523-5378.2009.00704.x · Cited by 281
Saad, R. J., Schoenfeld, P., Kim, H. M., & Chey, W. D. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00637.x · Cited by 261
Beta‐lactamase inhibitor enhances Helicobacter pylori eradication rate
Ojetti, V., Migneco, A., Zocco, M. A., Nista, E. C., Gasbarrini, G., & Gasbarrini, A. (2004) · Journal of Internal Medicine · doi:10.1046/j.0954-6820.2003.01239.x · Cited by 21
Self-citation
Metadata
- Authors
- Cammarota, G., Cianci, R., Cannizzaro, O., Cuoco, L., Pirozzi, G., Gasbarrini, A., Armuzzi, A., Zocco, M. A., Santarelli, L., Arancio, F., & Gasbarrini, G.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2000-10
- Volume
- 14
- Issue
- 10
- Pages
- 1339-1343
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1981314660
- Cited by
- 160
- References
- 1
- FWCI
- 10.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of two one‐week rabeprazole/levofloxacin‐based triple therapies for Helicobacter pylori infection. https://app.cochat.ai/papers/10.1046/j.1365-2036.2000.00846.x
- The paper
- Cammarota, G., Cianci, R., Cannizzaro, O., Cuoco, L., Pirozzi, G., Gasbarrini, A., Armuzzi, A., Zocco, M. A., Santarelli, L., Arancio, F., & Gasbarrini, G. (2000). Efficacy of two one‐week rabeprazole/levofloxacin‐based triple therapies for Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1046/j.1365-2036.2000.00846.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.